Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-24

FDA Approved: OXYBUTYNIN CHLORIDE EXTENDED RELEASE — Supplemental Application (Rising Pharma Holdings, Inc.)

View source ↗

Summary

FDA approved a supplemental application for oxybutynin chloride extended-release by Rising Pharma Holdings, Inc., confirming the product and its extended-releas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxybutynin chloride extended-release (Oxybutynin chloride)

Snippet

SUPPL AP for OXYBUTYNIN CHLORIDE EXTENDED RELEASE (OXYBUTYNIN CHLORIDE)